How can we help?

To learn more about our services get in touch on +44 20 7246 7800 or

Recent Russia research

* Russia: Nabiullina takes the controls, 11 Oct 2017
* Russia: US sanctions – a contrarian case, Christopher Granville, 28 Jul 2017
* Russia: Rates outlook – the key revealed, Christopher Granville, Madina Khrustaleva, 20 Jul 2017
* Russia: End of Putin revisited, Christopher Granville, 30 Jun 2017
* Russia: Geopolitics less bearish than oil, 23 Jun 2017

See all our Russia research >>

Russian pharma: from distribution to biotech


Russia’s pharmaceutical sector is aberrant in several respects. Total pharmaceutical spending relative to GDP is well below the OECD average, as this has not been a government priority. As a result, private demand untypically accounts for the bulk of the drugs market. Despite being thus embedded into Russia's dynamic new retail sector, pharmaceuticals fail to ride the middle-class consumer boom, since much of the natural demand comes from older and poorer people with less purchasing...

* Access to this publication is restricted

Request access

If you would like to read this publication, please enter your name and email address below:

Alternatively please call us on +44 20 7183 5280, or email

Already registered?